GeneDx Holdings Corp vs Wynn Resorts, Limited — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while Wynn Resorts, Limited trades at $75.33 (market cap $7.75B). The key difference: Wynn Resorts, Limited is far larger — about 3.8× GeneDx Holdings Corp's market cap, and Wynn Resorts, Limited pays a 1.33% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Wynn Resorts, Limited for 76 Days on average.
| WGS | WYNN | |
|---|---|---|
Market Cap | $2.02B | $7.75B |
Volume | 734,640 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $167.51 | $133.09 |
52-Week Low | $34.51 | $74.97 |
Typical Hold Time | 19 Days | 76 Days |
Enterprise Value | $2.05B | $17.99B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Wynn Resorts (WYNN) trades at $75.15, up 0.24% on the day, with a bearish technical signal driven by moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing margin pressure in the U.S. Revenue growth is supported by Macau strength, though high capital expenditure for new projects in the UAE and elevated debt levels present financial risks. Analyst consensus remains strongly bullish with a $132.36 price target, but recent institutional activity shows mixed positioning.
The outlook for WYNN hinges on Macau recovery and successful execution of expansion projects, offering potential upside from current levels. However, risks include rising capex, competitive pressures, and macroeconomic sensitivity. Investors should weigh strong analyst sentiment against fundamental challenges and debt load.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →